Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.
Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.
复制标题
99mTc-3PRGD2 整合素受体成像与 99mTc-MDP 骨扫描诊断肺癌骨转移的比较：一项多中心研究
DOI：
10.1371/journal.pone.0111221
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Jia B
中科院分区：
文献类型：
--
作者：
Miao W;Zheng S;Dai H;Wang F;Jin X;Zhu Z;Jia B
99mTC-3PRGD2是一种很有前途的整合素受体示踪剂，有望成为一种新型的肿瘤特异性单光子发射计算机断层扫描(SPECT)显像剂。本研究采用多中心前瞻性研究方法，以99mTC-MDP骨显像为对照，评价99mTC-3PRGD2显像对肺癌骨转移诊断的准确性。分别于静脉注射11.1MBq/kg 99mTc3PRGD2后1h和4h进行全身扫描和胸部断层扫描。1周内常规行99mTC-MDP全身骨显像作为对照。三位有经验的核医学医生盲目阅读99mTC-3PRGD2和99mTC-MDP图像。最终诊断建立在对所有可用数据的综合评估的基础上。4个中心共44例疑似肺癌患者，男性29例，年龄59±10岁。诊断为转移性病变18例89个，良性病变9例23个。在基于病变的分析中，99mTC-3PRGD2显像的敏感性、特异性和准确性分别为92.1%、91.3%和92.0%。在同一患者中，99mTC-MDP骨显像的诊断价值分别为87.6%、60.9%和82.1%。99mTC-MDP骨显像对大多数病灶具有较好的对比度，而99mTC-3PRGD2显像对排除假性阳性病变和发现无骨生成的骨转移灶似乎更有效。99mTC-3PRGD2是一种基于SPECT技术的新型肿瘤特异性显像剂，在肺癌骨转移的诊断中具有广阔的应用前景。临床试验.gov NCT01737112
99mTc-3PRGD2, a promising tracer targeting integrin receptor, may serve as a novel tumor-specific agent for single photon emission computed tomography (SPECT). A multi-center study was prospectively designed to evaluate the diagnostic accuracy of 99mTc-3PRGD2 imaging for bone metastasis in patients with lung cancer in comparison with the conventional 99mTc-MDP bone scan. The patients underwent whole-body scan and chest tomography successively at both 1 h and 4 h after intravenous injection of 11.1 MBq/Kg 99mTc-3PRGD2. 99mTc-MDP whole-body bone scan was routinely performed within 1 week for comparison. Three experienced nuclear medicine physicians blindly read the 99mTc-3PRGD2 and 99mTc-MDP images. The final diagnosis was established based on the comprehensive assessment of all available data. A total of 44 patients (29 male, 59±10 years old) with suspected lung cancer were recruited from 4 centers. Eighty-nine bone lesions in 18 patients were diagnosed as metastases and 23 bone lesions in 9 patients were benign. In a lesion-based analysis, 99mTc-3PRGD2 imaging demonstrated a sensitivity, specificity, and accuracy of 92.1%, 91.3%, and 92.0%, respectively. The corresponding diagnostic values for 99mTc-MDP bone scan were 87.6%, 60.9%, and 82.1%, respectively in the same patients. 99mTc-MDP bone scan had better contrast in most lesions, whereas the 99mTc-3PRGD2 imaging seemed to be more effective to exclude pseudo-positive lesions and detect bone metastases without osteogenesis. 99mTc-3PRGD2 is a novel tumor-specific agent based on SPECT technology with a promising value in diagnosis of bone metastasis in patients with lung cancer. ClinicalTrials.gov NCT01737112
登录
查看更多内容
影响因子：
4.7
作者：
Shi J;Kim YS;Chakraborty S;Jia B;Wang F;Liu S
通讯作者：
Liu S
影响因子：
9.3
作者：
Kenny, Laura M.;Coombes, R. Charles;Aboagye, Eric O.
通讯作者：
Aboagye, Eric O.
影响因子：
4
作者：
Costouros, NG;Diehn, FE;Libutti, SK
通讯作者：
Libutti, SK
影响因子：
56.9
作者：
BROOKS, PC;CLARK, RAF;CHERESH, DA
通讯作者：
CHERESH, DA
影响因子：
46.9
作者：
Pasqualini, R;Koivunen, E;Ruoslahti, E
通讯作者：
Ruoslahti, E